You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2025

Claims for Patent: 10,464,905

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,464,905

Title:	Compounds useful as kinase inhibitors
Abstract:	This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Inventor(s):	Guisot Nicolas
Assignee:	Loxo Oncology Inc.
Application Number:	US16113661
Patent Claims:	2. The method of claim 1 , wherein the cancer is selected from the group consisting of: lymphoma claim 1 , leukemia claim 1 , multiple myeloma claim 1 , a B-cell malignancy and bone cancer.3. The method of claim 2 , wherein the cancer is selected from: multiple myeloma claim 2 , diffuse large B cell lymphoma (DLBCL) claim 2 , follicular lymphoma claim 2 , mantle cell lymphoma claim 2 , marginal zone lymphoma claim 2 , Burkitt lymphoma claim 2 , Waldenstrom's macroglobulinemia claim 2 , chronic lymphocytic leukemia claim 2 , B-cell prolymphocyte leukemia claim 2 , and hairy cell leukemia.4. The method of claim 1 , wherein the cancer has one or more BTK inhibitor resistance mutations.5. The method of claim 4 , wherein the one or more BTK inhibitor resistance mutations is selected from the group consisting of C481S claim 4 , C481Y claim 4 , C481R claim 4 , and C481F.15. The method of claim 1 , wherein the compound is in the form of a pharmaceutically acceptable salt.17. The method of claim 16 , wherein the cancer is selected from the group consisting of: lymphoma claim 16 , leukemia claim 16 , multiple myeloma claim 16 , a B-cell malignancy and bone cancer.18. The method of claim 17 , wherein the cancer is selected from: multiple myeloma claim 17 , diffuse large B cell lymphoma (DLBCL) claim 17 , follicular lymphoma claim 17 , mantle cell lymphoma claim 17 , marginal zone lymphoma claim 17 , Burkitt lymphoma claim 17 , Waldenstrom's macroglobulinemia claim 17 , chronic lymphocytic leukemia claim 17 , B-cell prolymphocyte leukemia claim 17 , and hairy cell leukemia.19. The method of claim 16 , wherein the cancer has one or more BTK inhibitor resistance mutations.20. The method of claim 19 , wherein the one or more BTK inhibitor resistance mutations is selected from the group consisting of C481S claim 19 , C481Y claim 19 , C481R claim 19 , and C481F.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.